Omecamtiv mecarbil (BioDeep_00000662717)
代谢物信息卡片
Omecamtiv mecarbil (CK-1827452)
化学式: C20H24FN5O3 (401.1863)
中文名称: 4-[[2-氟-3-[N-(6-甲基吡啶-3-基)脲基]苯基]甲基]哌嗪-1-羧酸甲酯
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=NC=C(C=C1)NC(=O)NC2=CC=CC(=C2F)CN3CCN(CC3)C(=O)OC
InChI: InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27)
描述信息
C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent
同义名列表
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:188664
- KEGGdrug: D09648
- PubChem: 11689883
- DrugBank: DB11816
- ChEMBL: CHEMBL1800955
- CAS: 873697-71-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Po-Wei Chen, Ashit Trivedi, Edward Lee, Sandeep Dutta, Malidi Ahamadi. Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction.
Journal of cardiovascular pharmacology.
2022 04; 79(4):539-548. doi:
10.1097/fjc.0000000000001207. [PMID: 34983909] - Ashit Trivedi, Winnie Sohn, Cheng-Pang Hsu, Pegah Jafarinasabian, Hanze Zhang, Shauna Hutton, Stephen Flach, Siddique Abbasi, Sandeep Dutta, Edward Lee. Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects.
Clinical pharmacology in drug development.
2022 03; 11(3):388-396. doi:
10.1002/cpdd.1028. [PMID: 34634185] - Ashit Trivedi, Winnie Sohn, Pegah Jafarinasabian, Hanze Zhang, Bianca Terminello, Stephen Flach, Siddique Abbasi, Sandeep Dutta, Edward Lee. Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects.
Clinical pharmacology in drug development.
2022 01; 11(1):129-133. doi:
10.1002/cpdd.997. [PMID: 34272833] - Ashit Trivedi, Cheng-Pang Hsu, Pegah Jafarinasabian, Bianca Terminello, Hanze Zhang, Stephen Flach, Samuel Israel, Ashley Brooks, Hongqi Xue, Borje Darpo, Siddique Abbasi, Sandeep Dutta, Edward Lee. Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations.
British journal of clinical pharmacology.
2022 01; 88(1):187-198. doi:
10.1111/bcp.14939. [PMID: 34131942] - G Michael Felker, Scott D Solomon, Brian Claggett, Rafael Diaz, John J V McMurray, Marco Metra, Inder Anand, Marisa G Crespo-Leiro, Ulf Dahlström, Eva Goncalvesova, Jonathan G Howlett, Peter MacDonald, Alexander Parkhomenko, János Tomcsányi, Siddique A Abbasi, Stephen B Heitner, Thomas Hucko, Stuart Kupfer, Fady I Malik, John R Teerlink. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial.
JAMA cardiology.
2022 01; 7(1):26-34. doi:
10.1001/jamacardio.2021.4027. [PMID: 34643642] - Ashit Trivedi, Winnie Sohn, Priyanka Kulkarni, Pegah Jafarinasabian, Hanze Zhang, Marintan Spring, Stephen Flach, Siddique Abbasi, Jan Wahlstrom, Edward Lee, Sandeep Dutta. Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model.
Clinical and translational science.
2021 11; 14(6):2510-2520. doi:
10.1111/cts.13118. [PMID: 34415673] - Ashit Trivedi, Fady I Malik, Mia Mackowski, Shauna Hutton, Makoto Aoki, Siddique Abbasi, Sandeep Dutta, Edward Lee. Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects.
European journal of drug metabolism and pharmacokinetics.
2021 Nov; 46(6):759-770. doi:
10.1007/s13318-021-00711-2. [PMID: 34415561] - Ashit Trivedi, Jan Wahlstrom, Mia Mackowski, Sandeep Dutta, Edward Lee. Pharmacokinetics, Disposition, and Biotransformation of [14C]Omecamtiv Mecarbil in Healthy Male Subjects after a Single Intravenous or Oral Dose.
Drug metabolism and disposition: the biological fate of chemicals.
2021 08; 49(8):619-628. doi:
10.1124/dmd.121.000444. [PMID: 34011533] - Ashit Trivedi, Rajneet K Oberoi, Pegah Jafarinasabian, Hanze Zhang, Stephen Flach, Siddique Abbasi, Sandeep Dutta, Edward Lee. Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil.
Clinical pharmacokinetics.
2021 08; 60(8):1041-1048. doi:
10.1007/s40262-021-01014-0. [PMID: 33768487] - Yusheng Qu, BaoXi Gao, Ziva Arimura, Mei Fang, Hugo M Vargas. Comprehensive in vitro pro-arrhythmic assays demonstrate that omecamtiv mecarbil has low pro-arrhythmic risk.
Clinical and translational science.
2021 07; 14(4):1600-1610. doi:
10.1111/cts.13039. [PMID: 33955165] - Ashit Trivedi, Rajneet K Oberoi, Pegah Jafarinasabian, Hanze Zhang, Marintan Spring, Stephen Flach, Siddique Abbasi, Sandeep Dutta, Edward Lee. Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects.
Clinical drug investigation.
2021 Jul; 41(7):647-652. doi:
10.1007/s40261-021-01051-4. [PMID: 34097256] - Thomas D Bernier, Leo F Buckley. Cardiac Myosin Activation for the Treatment of Systolic Heart Failure.
Journal of cardiovascular pharmacology.
2021 01; 77(1):4-10. doi:
10.1097/fjc.0000000000000929. [PMID: 33165138] - BaoXi Gao, Weston Sutherland, Hugo M Vargas, Yusheng Qu. Effects of omecamtiv mecarbil on calcium-transients and contractility in a translational canine myocyte model.
Pharmacology research & perspectives.
2020 10; 8(5):e00656. doi:
10.1002/prp2.656. [PMID: 32969560] - Péter Nánási, Marta Gaburjakova, Jana Gaburjakova, János Almássy. Omecamtiv mecarbil activates ryanodine receptors from canine cardiac but not skeletal muscle.
European journal of pharmacology.
2017 Aug; 809(?):73-79. doi:
10.1016/j.ejphar.2017.05.027. [PMID: 28506910] - John R Teerlink, G Michael Felker, John J V McMurray, Scott D Solomon, Kirkwood F Adams, John G F Cleland, Justin A Ezekowitz, Assen Goudev, Peter Macdonald, Marco Metra, Veselin Mitrovic, Piotr Ponikowski, Pranas Serpytis, Jindrich Spinar, János Tomcsányi, Hans J Vandekerckhove, Adriaan A Voors, Maria Laura Monsalvo, James Johnston, Fady I Malik, Narimon Honarpour. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.
Lancet (London, England).
2016 12; 388(10062):2895-2903. doi:
10.1016/s0140-6736(16)32049-9. [PMID: 27914656] - John R Teerlink, G Michael Felker, John J V McMurray, Piotr Ponikowski, Marco Metra, Gerasimos S Filippatos, Justin A Ezekowitz, Kenneth Dickstein, John G F Cleland, Jae B Kim, Lei Lei, Beat Knusel, Andrew A Wolff, Fady I Malik, Scott M Wasserman. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.
Journal of the American College of Cardiology.
2016 Mar; 67(12):1444-1455. doi:
10.1016/j.jacc.2016.01.031. [PMID: 27012405] - Thuy Vu, Peiming Ma, Jim J Xiao, Yow-Ming C Wang, Fady I Malik, Andrew T Chow. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure.
Journal of clinical pharmacology.
2015 Nov; 55(11):1236-47. doi:
10.1002/jcph.538. [PMID: 25951506] - Barry H Greenberg, Willis Chou, Khalil G Saikali, Rafael Escandón, Jacqueline H Lee, Michael M Chen, Tatyana Treshkur, Irakli Megreladze, Scott M Wasserman, Paul Eisenberg, Fady I Malik, Andrew A Wolff, Tamaz Shaburishvili. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.
JACC. Heart failure.
2015 Jan; 3(1):22-29. doi:
10.1016/j.jchf.2014.07.009. [PMID: 25453536] - Mingru Zhang, Tiantian Mou, Zuoquan Zhao, Cheng Peng, Yunchuan Ma, Wei Fang, Xianzhong Zhang. Synthesis and 18F-labeling of the analogues of Omecamtiv Mecarbil as a potential cardiac myosin imaging agent with PET.
Nuclear medicine and biology.
2013 Jul; 40(5):689-96. doi:
10.1016/j.nucmedbio.2013.02.013. [PMID: 23566883] - John G F Cleland, John R Teerlink, Roxy Senior, Evgeny M Nifontov, John J V Mc Murray, Chim C Lang, Vitaly A Tsyrlin, Barry H Greenberg, Jamil Mayet, Darrel P Francis, Tamaz Shaburishvili, Mark Monaghan, Mitchell Saltzberg, Ludwig Neyses, Scott M Wasserman, Jacqueline H Lee, Khalil G Saikali, Cyril P Clarke, Jonathan H Goldman, Andrew A Wolff, Fady I Malik. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
Lancet (London, England).
2011 Aug; 378(9792):676-83. doi:
10.1016/s0140-6736(11)61126-4. [PMID: 21856481] - John R Teerlink, Cyril P Clarke, Khalil G Saikali, Jacqueline H Lee, Michael M Chen, Rafael D Escandon, Lyndsey Elliott, Rachel Bee, Mohammad Reza Habibzadeh, Jonathan H Goldman, Nelson B Schiller, Fady I Malik, Andrew A Wolff. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
Lancet (London, England).
2011 Aug; 378(9792):667-75. doi:
10.1016/s0140-6736(11)61219-1. [PMID: 21856480]
